Cost-effectiveness of boceprevir in patients previously treated for chronic hepatitis C genotype 1 infection in the United States. - Wikidata - wikimedia - TriplyDB

Cost-effectiveness of boceprevir in patients previously treated for chronic hepatitis C genotype 1 infection in the United States.

Cost-effectiveness of boceprevir in patients previously treated for chronic hepatitis C genotype 1 infection in the United States.

http://www.wikidata.org/entity/Q37286544

about

A systematic review of economic evaluations of treatments for borderline personality disorder Value of Treating All Stages of Chronic Hepatitis C: A Comprehensive Review of Clinical and Economic Evidence Outcomes and Costs of Treating Hepatitis C Patients in the Era of First Generation Protease Inhibitors - Results from the PAN Study.Cost-effectiveness of hepatitis C treatment using generic direct-acting antivirals available in India Direct-acting antivirals for chronic hepatitis C.Achieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefits Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States An observational study of the direct costs related to hospital admissions, mortality and premature death associated with liver disease in Portugal.Why We Should Be Willing to Pay for Hepatitis C Treatment.Incremental cost-effectiveness pharmacoeconomic assessment of hepatitis C virus therapy: an approach for less wealthy members of the common market.How to optimize current therapy of HCV genotype 1 infection with boceprevir.The cost-effectiveness of boceprevir for hepatitis C.Cost-effectiveness of protease inhibitor based regimens for chronic hepatitis C: a systematic review of published literature.Outcomes, costs and cost-effectiveness of treating hepatitis C with direct acting antivirals.Systematic Review of Modelling Approaches for the Cost Effectiveness of Hepatitis C Treatment with Direct-Acting Antivirals.Cost-effectiveness of elbasvir/grazoprevir use in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States.The cost-effectiveness of testing for NS5a resistance-associated polymorphisms at baseline in genotype 1a-infected (treatment-naïve and treatment-experienced) subjects treated with all-oral elbasvir/grazoprevir regimens in the United States.Optimal timing of hepatitis C treatment for patients on the liver transplant waiting list.Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection.Changing Cycle Lengths in State-Transition Models: Challenges and Solutions Cost-effectiveness of strategy-based approach to treatment of genotype 1 chronic hepatitis C.Hepatitis C Disease Burden in the United States in the era of oral direct-acting antivirals.Predictors of poor mental and physical health status among patients with chronic hepatitis C infection: the Chronic Hepatitis Cohort Study (CHeCS).Assessing the Effect of Potential Reductions in Non-Hepatic Mortality on the Estimated Cost-Effectiveness of Hepatitis C Treatment in Early Stages of Liver Disease.Cost-effectiveness analysis of sofosbuvir-based regimens for chronic hepatitis C.Transplanting HCV-positive livers into HCV-negative patients with preemptive antiviral treatment: A modeling study.Hepatitis C virus re-treatment in the era of direct-acting antivirals: projections in the USA.Should we treat acute hepatitis C? A decision and cost-effectiveness analysis.Theoretical Foundations and Practical Applications of Within-Cycle Correction Methods.Cost-effectiveness analysis of elbasvir-grazoprevir regimen for treating hepatitis C virus genotype 1 infection in stage 4-5 chronic kidney disease patients in France.Cost/Benefit of Hepatitis C Treatment: It Does Not End with SVR.Cost-effectiveness of diagnostic and therapeutic interventions for chronic hepatitis C: a systematic review of model-based analyses.Direct-acting antivirals for chronic hepatitis C

P2860

Q27010205-0E4616A1-95B5-4AA0-96CE-302B0C097FE7 Q28072257-13AAEA27-2CE1-4134-BDF5-D183FDF24647 Q30376341-DDE12A47-4926-49DF-A854-AF77AA90806A Q33698956-4CFDB913-EE78-4F17-A247-51C6E08807F2 Q34557595-08586BA2-45B6-4781-AD06-6DD33DFE508A Q34987336-4F1BD956-23B0-46C0-9651-F0DEE183E908 Q35619161-09EA2A77-7FBC-4051-87EB-CB8A0BB8D719 Q35914175-05AD8489-421F-4F1E-9E4A-DF1D23E5A31B Q36075161-E06D370F-620E-49B0-943F-F179395AC177 Q37555115-1BE6970F-42B3-4DE9-99D8-13F72A0CFA46 Q38174241-897F8A50-B2FB-48FE-AD26-182CBD30A5FB Q38202682-73B4BBBE-FB83-423E-B211-C4B5650A14BA Q38206573-6B318F32-78EA-430F-A273-2A4EAE20532E Q38470584-BF3105DC-2563-4C16-80FB-C34B1ED65995 Q38691333-6841E3BF-6731-4D8D-BF98-10B89A5FB263 Q39102936-42DED06A-EA2F-4E5D-91A9-25C60292F947 Q39137372-0C91ECE5-C69A-446F-AB6D-890967C0B6CE Q39139767-5A06EFF7-82EF-4E4A-9994-95FBD5E20A7E Q39153261-D4EF5CA5-E59A-4622-A9DC-DE1DED66EC71 Q39638320-3346A492-7315-4ADD-9C8F-E7751FD0EDB9 Q39910149-5B413DAD-AAA5-455C-9A25-DF74A2FF2572 Q40528873-F56CBF33-F0E5-45D1-9242-44C42B046AC1 Q41746574-B8239B92-2750-4467-9C58-C61B6D9DA029 Q42048758-483576D5-CB0F-4DF2-8655-D40AB76F54FF Q45050419-CACCC40C-33FE-4E9E-8D89-59D0226F5B65 Q46626377-A994605A-B71F-4895-9A11-BE281944440B Q47548368-85E47C3A-5415-4038-B00A-6934215DFE08 Q47603693-2004620C-BC8E-48FF-B687-A0B0AACFC48B Q48787840-1433342A-5035-4AC8-8077-02F738463C7C Q52653977-EB5F1681-97B9-43E0-A60F-A2098CF2D647 Q54254113-37219A9D-CC73-42DB-B910-83953A3259D7 Q55280669-04B6E47C-0BD1-4F75-9CF0-7419938A8EC0 Q57389418-068E2734-9B4C-452A-BD9E-AA04168EC722

P2860

Cost-effectiveness of boceprevir in patients previously treated for chronic hepatitis C genotype 1 infection in the United States.

http://www.wikidata.org/entity/Q37286544

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on September 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Cost-effectiveness of boceprev ...... nfection in the United States.

@en

Cost-effectiveness of boceprev ...... nfection in the United States.

@nl

type

label

Cost-effectiveness of boceprev ...... nfection in the United States.

@en

Cost-effectiveness of boceprev ...... nfection in the United States.

@nl

prefLabel

Cost-effectiveness of boceprev ...... nfection in the United States.

@en

Cost-effectiveness of boceprev ...... nfection in the United States.

@nl

P1433

Q37286544-18F4422E-33E7-4FC2-814A-C8729BE3F01F

P1476

Q37286544-FD2A5D62-9D27-4911-8DAC-F97421DF28E7

P2093

Q37286544-04A4B34A-C7F6-480E-B393-08271EEBBA25

Q37286544-129646EC-8F00-41BD-B3BE-41B277D3D1D0

Q37286544-54A6F6BC-C6C2-4282-B5D3-DE6928149BB7

Q37286544-58D1488B-5496-4C9D-82B0-BE8071D68001

Q37286544-6390ECE0-BD59-4890-A0C9-0F2365FC1108

Q37286544-72944A9E-D23E-4C14-BE65-C1121A5B56FB

Q37286544-E79F6C94-92D1-43E8-BA52-0E7D39293B73

P2860

Q37286544-00DF3A20-5E42-4B29-AB33-4F528420AAA3

Q37286544-036647E8-429B-4A3B-98B5-DB23AE416581

Q37286544-0B2B40B9-B7E4-4C38-9EBC-41CA471BEF4E

Q37286544-0D37B71A-96B4-4E43-9BAD-716BDBA273BA

Q37286544-0E9E4720-7FA2-4D0D-9078-7552819A6F49

Q37286544-15821C80-0338-4080-BFF0-9AD331A6BE5A

Q37286544-1C31AEBE-B4E5-4EC6-9FA8-8DCA37D8A299

Q37286544-1DF9D4E8-EE0E-47A1-939E-C350F99B8201

Q37286544-21AD27AB-E27F-4D9E-96F0-93E72152373E

Q37286544-21ED3826-3D82-4CE7-806E-F2A63A364FE6

P304

Q37286544-BCA48C7A-37F8-4703-9560-EB09A5ABF7CF

P31

Q37286544-D9D5F1BE-53DE-4107-BD64-0633AFDF3CE6

P356

Q37286544-980DE9E4-62FA-4D7A-A5C2-34608E429A5F

P433

Q37286544-4CA7FB4C-4FC3-4C63-8FCB-4C396ED31933

P478

Q37286544-FA279A46-EDFE-48F1-AB90-CD28CC74C832

P50

Q37286544-15A6FF0A-41E6-4FF2-A6E7-9B49B6B72F0C

P577

Q37286544-1B76929B-124D-434C-8963-BF5493308B71

P5875

Q37286544-FF511A32-3B0F-48AA-8035-45A6BC733D0F

P698

Q37286544-E84945A9-8C6E-40FC-B5A0-EC6D156C0489

P921

Q37286544-0A660C7F-16F4-4486-9C77-28838A0BD114

Q37286544-1EBB04B6-74F7-4C7F-BD13-D574047C0F56

P932

Q37286544-C3B0B5C4-E2EE-4D97-A3A8-9BB5B2F58EB4

P356

J.JVAL.2013.07.006

P1433

Value in Health

P1476

Cost-effectiveness of boceprev ...... nfection in the United States.

@en

P2093

Antoine C El Khoury

http://www.w3.org/2001/XMLSchema#string

Bruce Bacon

http://www.w3.org/2001/XMLSchema#string

Cliff Brass

http://www.w3.org/2001/XMLSchema#string

Elamin H Elbasha

http://www.w3.org/2001/XMLSchema#string

Jagpreet Chhatwal

http://www.w3.org/2001/XMLSchema#string

Margaret Burroughs

http://www.w3.org/2001/XMLSchema#string

Shannon A Ferrante

http://www.w3.org/2001/XMLSchema#string

P2860

Boceprevir for previously treated chronic HCV genotype 1 infection

An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

Diagnosis, management, and treatment of hepatitis C: an update

Telaprevir for retreatment of HCV infection

Telaprevir for previously untreated chronic hepatitis C virus infection

Boceprevir for untreated chronic HCV genotype 1 infection

Medicare program; changes to the hospital inpatient prospective payment systems and fiscal year 2008 rates.

Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C.

Long course and prognostic factors of virus-induced cirrhosis of the liver.

P304

973-986

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JVAL.2013.07.006

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

256663995

http://www.w3.org/2001/XMLSchema#string

P698

24041347

http://www.w3.org/2001/XMLSchema#string

P921

Ameeriga Ütisriigiq

P932

3820000

http://www.w3.org/2001/XMLSchema#string